TIDMHIK
RNS Number : 0388A
Hikma Pharmaceuticals Plc
01 October 2009
Block Listing of Shares
Hikma Pharmaceuticals PLC
LONDON, 1 October 2009 - The Board of Hikma Pharmaceuticals PLC ("Hikma") (LSE:
HIK) (NASDAQ: HIK), announces that it has made a block listing application to
the Financial Services Authority and the London Stock Exchange plc for a total
of 3,000,000 ordinary shares of 10p each in the capital of the Company to be
admitted to the Official List of the UK Listing Authority. It is expected that
admission will be granted on 2 October 2009 and trading will commence on 5
October 2009.
The shares, when issued, will be issued fully paid and rank pari passu in all
respects with the existing issued ordinary shares of the Company. The shares
will be issued pursuant to the exercise of options under the Hikma
Pharmaceuticals PLC 2004 Stock Option Plan (the "Plan"). Participants in the
Plan have or will become entitled to these shares following the vesting and
exercise of options over shares.
For further information, please contact:
Henry Knowles, Company Secretary
Hikma Pharmaceuticals PLC+44 20 7399 2760
Susan Ringdal, Investor Relations Director
Hikma Pharmaceuticals PLC+44 20 7399 2760
About Hikma
Hikma Pharmaceuticals PLC is a fast growing multinational group focused on
developing, manufacturing and marketing a broad range of both branded and
non-branded generic and in-licensed pharmaceutical products. Hikma's operations
are conducted through three businesses: "Branded", "Injectables" and "Generics".
Hikma's operations are based principally in the Middle East and North Africa
("MENA") region, where it is a market leader and sells across 17 countries, the
United States and Europe. In 2008, the Group achieved revenues of $580.7
million (2007 $449 million) and profit attributable to shareholders was $57.1
million (2007 $63 million). For news and other information, please visit
www.hikma.com.
This information is provided by RNS
The company news service from the London Stock Exchange
END
LISUUGRUUUPBUBG
| 
